

September, 2016

Newsletter

News

Tailored algorithm for the Chronic Disease Score



Various measures of total disease burden have been developed over the years. At PHARMO, a tailored algorithm was developed to assign a 'chronic disease score' to a patient based on drug use derived from medication records in the PHARMO Database Network, reflecting chronic disease severity.



Events

PhUSE Conference: PHARMO's uniform analysis approach for multi-country studies



PHARMO has built up quite some experience with coordinating multi-country studies. At the 2016 PhUSE conference PHARMO is one of the first contributors to the new RWE stream, explaining the PHARMO approach of using study specific common data models, and shared SAS stored compiled macro catalogs to ensure identical analyses across countries.



Publications

PHARMO study published in the BMJ



PHARMO was involved in a multi-database study on pioglitazone use and risk of bladder cancer in patients with type 2 diabetes, which was recently published in the BMJ. The results of this study indicate that there is no evidence of an association between the risk of bladder cancer and the use of pioglitazone compared to the use of other antidiabetic drugs. The PHARMO team also contributed to recently published studies on prostate surgery and acute urinary retention, drug dispensings prior to colon cancer diagnosis and prescription behaviour following communications regarding clopidogrel – proton pump inhibitor interactions.

